RxDoctor Payments Data

Lynley Holt, MD

Family Medicine · Asheboro, NCNPI 1043471329

Payments from drug & device makers

$13,222in general payments, 2019–2025

Across 827 payments — averaging $15.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • AbbVie$1K
  • Boehringer Ingelheim$786
  • Pfizer$736
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$13,196100%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk121$1,631
AstraZeneca79$1,262
Lilly USA, LLC81$1,229
AbbVie(2 entities)95$1,148
Boehringer Ingelheim41$786
Pfizer58$736
Preventric Diagnostics, Inc.1$605
GSK38$519
Amgen30$441
Merck24$383
Axsome Therapeutics, Inc.5$317
Bayer18$285
Astellas Pharma US Inc19$261
Amarin Pharma, Inc.16$216
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC12$197
Exact Sciences10$187
Takeda Pharmaceuticals U.S.A., Inc.12$177
Sanofi-aventis U.S. LLC10$170
Eisai Inc.9$163
Esperion Therapeutics, Inc.8$149
Johnson & Johnson10$143
Teva Pharmaceuticals USA, Inc.8$126
Otsuka America Pharmaceutical, Inc.6$120
Cranial Technologies, Inc7$113
Sumitomo Pharma America, Inc.7$110
Biohaven Pharmaceuticals, Inc.4$101
Novartis7$94
Kowa Pharmaceuticals America, Inc.7$87
Biohaven Pharmaceutical Holding Company Ltd.4$71
Daiichi Sankyo Inc.4$66
Genentech USA, Inc.4$61
Avion Pharmaceuticals4$60
Baxter Healthcare2$60
Ironwood Pharmaceuticals, Inc4$58
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$56
Xeris Pharmaceuticals, Inc.4$56
Corium, LLC3$49
Philips North America LLC1$48
Supernus Pharmaceuticals, Inc.3$48
Corcept Therapeutics3$47
Mylan Specialty L.p.2$47
Lundbeck LLC3$45
Neotract Inc.1$43
Sunovion Pharmaceuticals Inc.3$41
Seqirus USA Inc2$38
Medtronic2$35
Abbott2$35
Vanda Pharmaceuticals Inc.2$35
Idorsia Pharmaceuticals US Inc2$34
Neurocrine Biosciences, Inc.2$30
Dexcom, Inc.2$30
Currax Pharmaceuticals LLC2$30
Novavax Inc1$26
Organogenesis Inc.1$24
Sanofi Pasteur Inc.1$23
Arbor Pharmaceuticals, Inc.1$20
Amneal Pharmaceuticals LLC1$19
Exeltis, USA Inc.1$19
Collegium Pharmaceutical, Inc.1$18
Shire North American Group Inc1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,222 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$121,570
Medicare patients
261
Services billed
2,938

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban137$110,242
OzempicSemaglutide61$77,088
MounjaroTirzepatide36$62,627
JardianceEmpagliflozin76$57,972
FarxigaDapagliflozin Propanediol37$38,208
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$37,740
ProliaDenosumab21$37,048
RexultiBrexpiprazole13$35,046
XareltoRivaroxaban43$31,639
JanuviaSitagliptin Phosphate30$28,188
Breztri AerosphereBudesonide/Glycopyr/Formoterol36$28,076
RybelsusSemaglutide17$25,193
TradjentaLinagliptin29$24,015
MyrbetriqMirabegron23$23,666
LinzessLinaclotide17$19,418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$736$110,242137 claims
Novo NordiskOzempic, Rybelsus$1,631$102,28178 claims
Boehringer IngelheimJardiance, Tradjenta$786$81,987105 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,262$72,89587 claims
Lilly USA, LLCMounjaro$1,229$62,62736 claims
GSKTrelegy Ellipta, Anoro Ellipta$519$42,98252 claims
AmgenProlia$441$37,04821 claims
Otsuka America Pharmaceutical, Inc.Rexulti$120$35,04613 claims
Johnson & JohnsonXarelto$143$31,63943 claims
MerckJanuvia$383$28,18830 claims
AbbVieLinzess, Synthroid$1,148$27,07193 claims
Astellas Pharma US IncMyrbetriq$261$23,66623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Asheboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →